Background: Epoxyeicosatrienoic acids (EETs) are natural angiogenic mediators regulated by soluble epoxide hydrolase (sEH). Inhibitors of sEH can stabilize EETs levels and were reported to reduce atherosclerosis and inhibit myocardial infarction in animal models. In this work, we investigated whether increasing EETs with the sEH inhibitor t-AUCB would increase angiogenesis related function in endothelial progenitor cells (EPCs) from patients with acute myocardial infarction (AMI). Methods and results: EPCs were isolated from 50 AMI patients and 50 healthy subjects (control). EPCs were treated with different concentrations of t-AUCB for 24 h with or without peroxisome proliferator activated receptor γ (PPARγ) inhibitor GW9662. Migration of EPCs was assayed in trans-well chambers. Angiogenesis assays were performed using a Matrigel-Matrix in vitro model. The expression of vascular endothelial growth factor (VEGF), hypoxia-inducible factor 1α (HIF-1α) mRNA and protein in EPCs was measured by real-time PCR or Western blot, respectively. Also, the concentration of EETs in the culture supernatant was detected by ELISA. The activity of EPCs in the AMI patient group was reduced compared to healthy controls. Whereas increasing EET levels with t-AUCB promoted a dose dependent angiogenesis and migration in EPCs from AMI patients. Additionally, the t-AUCB dose dependently increased the expression of the angiogenic factors VEGF and HIF-α. Lastly, we provide evidence that these effects were PPARγ dependent.
Introduction
Acute myocardial infarction (AMI) and subsequent ischemic heart failure are well known worldwide health problems and leading causes of morbidity and mortality. AMI is an ischemic disease; thus, therapy that promotes revascularization is beneficial. Endothelial progenitor cells (EPCs) are hematopoietic, bone-marrow-derived cells that express CD34 and vascular endothelial growth factor receptor 2 and differentiate into endothelial cells [1] . Evidence suggests that EPCs play important roles in vasculogenesis and reendothelialization after ischemic injury by migrating and adhering to the site of injury and differentiating into vascular endothelial cells (ECs) [2, 3] .
Soluble epoxide hydrolase inhibitors (sEHi) have multiple protective effects on the cardiovascular system [4] [5] [6] and are thought to act by blocking the conversion of epoxyeicosatrienoic acids (EETs) to their less active and sometimes inflammatory corresponding diols by soluble epoxide hydrolase (sEH) [7, 8] . EETs have multiple biological functions, such as causing marked vasodilation, inhibiting migration of vascular smooth muscle cells, decreasing inflammatory reactions, inhibiting platelet aggregation, promoting fibrolysis, and decreasing the expression of adherence factor [9] [10] [11] . In addition, EETs can modulate lipid metabolism and insulin resistance [12] . Most importantly, EETs have been suggested to contribute to neovascularization by promoting angiogenesis [13] . Inhibiting sEH can increase the beneficial effects of EETs in animal models of hypertension, atherosclerosis, ischemic heart disease, myocardial hypertrophy, heart failure, diabetes and metabolic syndrome [14] [15] [16] [17] [18] [19] [20] . Therefore, we tested the hypothesis that the sEHi, t-AUCB (trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid), will improve the angiogenic function of EPCs from AMI patients in order to explore the potential effect of sEHi in treating acute myocardial infarction. We further hypothesized that the EETs-PPARγ pathway is responsible for the mechanism underlying the effect of t-AUCB on EPCs.
Materials and methods

Reagents
t-AUCB was synthesized as described [21] . EBM-2 (Lonza); Ficoll-1077, human fibronectin, and FITC-UEA-I (Sigma); DiI-acLDL (Molecular Probes); Matrigel-Matrix (BD Biosciences); polyclonal rabbit anti-VEGF, HIF-α (Abcam) were used without further purification.
Study subjects
Fifty hospitalized primary ST segment-elevated AMI patients (29 males and 21 females) ranging in age from 55 to 75 years old (average age 58.42 ± 5.37 years) and having a Killip grade 1 heart function were enrolled in the study, which occurred May 2009 to December 2011. Fifty age and sex matched healthy subjects were recruited as controls.
The diagnosis of AMI was defined as the presence of severe chest pain for at least 20 min and electrocardiographic signs for AMI, which included ST-segment elevation of at least 0.1 mV in two or more limb leads or at least 2 mV in two or more contiguous precordial leads on the surface electrocardiogram. AMI diagnosis also included markers of myocardial necrosis, such as Troponin T, being elevated and creatine kinase-MB isoenzyme levels >2 times the upper limit of normal. Characteristics of the study subjects are shown in Table S1 in the Supplemental material.
Patients were excluded from the study if they were > 75 years old and had a severe disease(s), including heart failure, acute liver disease or hepatic dysfunction, primary hypothyroidism, and nephrotic syndrome. Patients with a history of malignancy, cerebrovascular diseases or using prohibited medications or immunosuppressive drugs were also excluded.
The study conformed to the Declaration of Helsinki, and all the study protocols were approved by the Ethical Board of Central South University. All enrolled subjects were given fully informed consent prior to entry in the study.
After enrollment, patients underwent a routine physical examination and lipoproteins, fasting blood glucose (FBS), and liver and kidney functions were measured.
EPCs isolation culture and identification
EPCs were obtained as previously described [22] . Briefly, human blood was collected from AMI patients immediately after admission. All enrolled patients were hospitalized within 24 h after a heart attack. Blood from healthy subjects was taken as the control. Human peripheral mononuclear cells (PBMC) were isolated by subsequent purification over Ficoll gradients and cultured at a density of 5 × 10 5 /cm in endothelial cell basal medium-2 (EBM-2) with 10% FBS supplemented with vascular endothelial growth factor (VEGF), epidermal growth factor, fibroblast growth factor, insulin-like growth factor, ascorbic acid, hydrocortisone, heparin and antibiotics, according to the manufacturer's instructions (Singlequots, Lonza). Cells were plated on human fibronectin coated culture dishes. After 4 days of culture, non-adherent cells were removed. Adherent cells were cultured for another 3 days.
We were limited to 20 mL of blood per blood draw. For this reason it was necessary to pool PBMC from 4 to 5 patients' blood to culture. We isolated EPCs from the pooled sample ten different times from the 50 AMI patients and repeated the same process for the controls to get ten independent cultures of EPCs per group.
To test whether or not these adherent cells were EPCs, positive double staining for both Dil-labeled acetylated low density lipoprotein (Dil-acLDL) (10 μg/mL, Sigma) and FITC-labeled Ulex europaeus agglutinin I (FITC-UEA-I) (10 μg/mL, Sigma) was visualized by fluorescence microscopy [23] . EPC expression of antigen CD34, CD133, CD31, and VEGFR2 was detected by flow cytometry [24, 25] . Isotype controls were used as negative controls.
Method of challenging the EPCs
After starving EPCs from AMI patients for 24 h, 0, 10
, 10
, and 10 − 4 mol/L of t-AUCB were added to the cells for 24 h. EPCs from healthy subjects were cultured in the same manner.
To further evaluate the functional role of the PPARγ pathway on the effects of t-AUCB on EPCs, we used the antagonist of PPARγ, GW9662. EPCs were preincubated with GW9662 (5 μmol/L) half an hour before 10 − 4 mol/L t-AUCB was added [26] .
Migration assay
EPCs (5 × 10 4 ) were transferred into the upper chambers of a modified Boyden's chamber (transwell, Millipore) filled with EBM-2 media, as described previously [27] . The lower chambers were loaded with phenol red free EBM alone or a different concentration of t-AUCB with or without 5 μmol/L of GW9662. EPCs were allowed to migrate for 10 h, after which non-migrated EPCs were removed. Cells were fixed by paraformaldehyde and then stained with hematoxylin and eosin (H&E). The number of cells on the lower side of the membrane was counted at magnification × 200, and the mean value of ten different areas was determined for each sample.
In vitro angiogenesis assay
Briefly, EPCs were trypsinized and resuspended in medium to inactivate trypsin. After centrifugation, the medium was removed and the cells were resuspended in plain EBM-2. Reconstituted Matrigel-Matrix (BD Biosciences) was placed in a 48-well cell culture plate, and 5 × 10 4 EPCs were plated in each well with phenol red-free EBM-2 and various stimuli. After 48 h of incubation, images of tube morphology were taken with an inverted microscope (Nikon). Capillary tube lengths were measured in 10 random low power fields (×100) per sample by investigators who were unaware of the study's purpose. A capillary tube was defined as a tubular structure whose length was four times its width [28] .
Real-time PCR analysis
Total RNA from 1 × 10 6 cells was harvested by TRIZOL (Invitrogen) according to the manufacturer's instructions. The extracted RNA was dissolved in a final volume of 25 μL RNase free water, and concentrations of the total RNA were tested using a spectrophotometer. First-stranded cDNA was synthesized from 1 μg total RNA (Fermentas Life Science). Real-time PCR was performed with the SYBR Premix Ex TaqII Kit (TaKaRa). The primers were: VEGF F: 5′-GCTACTGCCGTCCGATTGA-3′, R:5′-TGCTGGC TTTGGTGAGGTT-3′; HIF-α: F:5′-CTCGGCGAAGCAAAGAG-3′, R:5′-GCCATCTAGGGC TTTCAG-3′; GAPDH: F:5′-TGACCGGGTCACCCACACTGTGCCCATCTA-3′, R:5′-CTAGAA GCATTTGCG GTGGACGATGGAGGG-3′. PCR was performed in triplicate using a real time PCR machine (Applied Bioscience). The mRNA levels were estimated from the value of the threshold cycle (Ct) of the real-time PCR adjusted by that of GAPDH through the formula 2Δ Ct (ΔCt = GAPDH Ct gene of interest Ct).
Western blot
Protein samples were separated from the total cell lyates by SDS-PAGE and transferred to PVDF membranes (Amersham Biosciences, NJ). After incubating with primary and secondary antibodies, the immunoblots were exposed to Hyperfilm-ECL (Amersham-PharmaciaBiotech, NJ) films and analyzed using an imaging system (Alpha Innotech, CA) to obtain densitometric values. β-actin was utilized as the internal control.
Measurement of EETs
Culture supernatants were collected, and the anti oxidant reagent triphenylphosphine (TPP) was added to the supernatant. Aliquots were kept at −80°C until analysis. The concentration of EETs was measured by the 14, 15-EETs/DHET Elisa kit (Detroit R&D) according to the protocol provided in the kit.
Statistical analysis
All experiments were performed at least ten times in duplicate. Each experiment was considered to be independent. Results are expressed in mean ± SEMs. Comparison of continuous variables was performed by paired student's t test. Differences in selected categorical variables between the respective comparison groups were analyzed with the χ 2 test of statistical significance. Comparison between the in vitro experimental groups was performed by using one way ANOVA. LSD and S-N-K post-hoc tests were used for comparison. A value of p b 0.05 (2-sided) was considered statistically significant.
Results
Baseline clinical characteristics of the patients
The baseline characteristics of the study population are summarized in Table S1 in Supplemental material. Both AMI and healthy control groups were similar with regard to age, gender and body mass index. Furthermore, there were no significant differences in liver and kidney functions at baseline between the two groups (all p > 0.05). The total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-C) in AMI patients was slightly higher than those in the control group, however there was no statistical difference between those two groups (all p > 0.05). However, the FBS and white blood cell (WBC) count were substantially higher in the AMI than in control (pb 0.05). The percentage of the smoking, diabetes and family history of coronary heart disease in AMI patients were high.
Culture results of EPCs from peripheral blood
Outgrowth colonies of adherent cells were found 2 to 3 days after plating ( Fig. S1a in supplement) . After 5-6 days of culture, EPCs were differentiated into an adherent population characterized by a central cluster of round cells with many sprouts of elongated cells at the periphery defined as a colony-forming unit-EPC (Fig. S1b-c in supplement) . These colonies proliferated rapidly and exhibited spindleshaped or cobblestone morphology. After 10-14 days, the cells formed a monolayer of spindle-shaped flat cells (Fig. S1d in supplement) .
Characterization of human EPCs
EPCs incorporated acLDL and stained positive for Dil-acLDL (red color, Fig. S2a in supplement) . EPCs also were stained positive for FITC-labeled lectin (green color) ( (Fig. S3c-d in supplement) , which confirmed that those cells had an endothelial lineage. Based on those basic characterizations, we used EPCs after 7-8 days of culture.
Effects of t-AUCB on EPCs migration from AMI patients
The first, critical step of the revascularization process is migration of EPCs to the site of injury. Therefore, the effect of t-AUCB on the migration activity of EPCs was assessed using a modified Boyden chamber apparatus in the presence or absence of t-AUCB. As shown in Fig. 1b , the migration ability of EPCs from AMI patients without t-AUCB treatment (0 mol/L t-AUCB group) was markedly decreased as compared to those from healthy control (pb 0.05) (Fig. 1a) . t-AUCB augmented the migratory activity of EPCs in a dose dependent manner, 10 (Fig. 1b-e) (Table 1) . To further investigate the involvement of PPARγ pathway in the effects of t-AUCB on EPCs, we pretreated cells with PPARγ antagonist GW9662 (5 μmol/L) before stimulation with 10 − 4 mol/L t-AUCB. As shown in Fig. 1f , pretreatment with GW9662 markedly attenuated the migratory ability of EPCs from AMI patients responding to t-AUCB (pb 0.05) (Fig. 1f) ( Table 1) .
Effects of t-AUCB on in vitro angiogenesis of EPCs from AMI patients
EPCs can differentiate into mature endothelial cells in situ and form capillary-like tubes. This process requires several biological activities, such as endothelial cell proliferation, cell migration, protease secretion and cell-to-cell interaction. The effect of t-AUCB on the in vitro angiogenesis activity of EPCs, namely in vitro capillary tube formation, was evaluated. Compared with those from healthy control (Fig. 2a) , the EPCs capillary tube formation of from AMI patients (0 mol/L t-AUCB group) were markedly reduced compared to control patients (p b 0.05, Fig. 2b ), whereas t-AUCB increased the activity of in vitro capillary tube formation in a dose dependent manner. 10 − 6 , 10 − 5 , and 10 − 4 mol/L of t-AUCB significantly increased the activity of in vitro capillary tube formation of EPCs (Fig. 2, b -e, p b 0.05) (Table 1 ), but tube formation was severely impaired by adding GW9662 with t-AUCB (p b 0.05) (Fig. 2f) ( Table 1 ).
Effects of t-AUCB on the mRNA expression of VEGF, HIF-1α
As shown in Fig. 3 , compared with those from healthy control, the mRNA expression of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1α (HIF-1α) was decreased (p b 0.05) in ischemic patients, whereas they were increased by t-AUCB in a dose dependent manner, 10 
Effects of t-AUCB on the protein expression of VEGF and HIF-1α
Consistent with the levels of mRNA expression, compared with those from healthy controls (Fig. 4 column a) , the protein expression of VEGF, and HIF-1α were attenuated in EPCs from AMI patients without t-AUCB treatment (p b 0.05) (Fig. 4 column b) , whereas increased with t-AUCB treatment in a dose dependent manner (Fig. 4 (p b 0.05) (Fig. 4, lower figure) . However, as shown in Fig. 4 column f, pre-treating EPCs with GW 9662 reduced the VEGF, HIF-1α protein expression.
Measurement of EETs concentration
The EETs concentration in the cell culture supernatant of EPCs from AMI patients without t-AUCB treated (0 mol/L t-AUCB group) were statistically lower than that of healthy control (p b 0.05) ( Table 2 ), but the concentration of EETs was statistically increased in a dose dependent manner after treated by 10 − 6 , 10 (Table 2 ).
Discussion
These results demonstrate a potential role of the sEH inhibitor t-AUCB in promoting angiogenesis and migration of EPCs. The present findings also show that t-AUCB can increase the expression of angiogenic factors VEGF and HIF-1α and that these effects appear to be PPARγ dependent.
Acute myocardial infarction (AMI) is an acute ischemic event; therefore, restoring coronary blood circulation by stimulating new blood vessel formation is of primary importance [29] . Circulating bone marrow derived cells, defined as early endothelial progenitor cells (EPCs), can proliferate multiple times and differentiate into endothelial cells [30, 31] . Recent studies have shown that mobilization and differentiation of EPCs plays an important role in augmenting neovascularization and endothelial replacement in the ischemic and injured heart [32] [33] [34] . Increased numbers and mobility of circulating EPCs have been reported after ischemia, vascular injury, and in the early phase after AMI [35] [36] [37] [38] [39] . In contrast, other studies have demonstrated that the mean circulating level and migratory activity of EPCs is notably lower in AMI patients than in normal control subjects [40] [41] [42] [43] .
In the present study, we found that the migratory and angiogenic properties of EPCs from AMI patients were markedly attenuated as compared with healthy controls. A reasonable explanation for this result is that the patients in the present study had more risk factors compared to the controls, such as smoking and hypertension (Table  S1 in Supplement material), the number and migratory activity of Table 1 Effects of t-AUCB on the activity of migration and in vitro tube formation of EPCs from AMI patients (mean ± SEM) (n = 10). circulating EPCs were inversely correlated with the number of risk factors for coronary artery disease [42] . Another reason could be that the blood samples were drawn before early revascularization caused by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) were used, which have positive effects on EPCs in other studies. [44, 45] . Although those AMI patients who had high risk factors in the present study routinely used antihypertension drugs such as angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor inhibitors (ARB), calcium channel blockers (CCB) and hypoglycemic agents or insulin were, which was reported had positive effects on the function of EPCs [46] [47] [48] , the results of the present study still showed ability of EPCs in AMI patients were markedly attenuated which suggests that the ability of EPCs in AMI patients was ineffective and insufficient to match the demand of the neovascularization of the ischemic issues after injury. EPCs augment angiogenesis not only by providing a source of progenitor cells that can differentiate into mature vascular endothelial cells, but also by stimulating the secretion of angiogenic growth factors at the site of incorporation. These would enhance growth and differentiation of EPCs in an autocrine manner [49] [50] [51] . VEGF and HIF-1α are two of the most powerful angiogenic factors for blood vessels [52] . VEGF is crucial for preservation of the microvasculature [53] , whereas HIF-1α is the most important transcription factor driving VEGF mRNA expression and production [54, 55] . In this regard, increasing VEGF and HIF-1α in EPCs has the potential to be beneficial to AMI patients. The present study showed that the VEGF and HIF-1α mRNA and protein expressions in AMI patients' EPCs were much lower than in the healthy controls, which might partly explain the inadequate angiogenic ability of EPCs in the AMI patients. Most importantly, our study showed that the mRNA and protein expression of VEGF and HIF-1α was dose dependently increased by t-AUCB and the migration and angiogenesis ability of EPCs were markedly increased at the same time. These results suggest that t-AUCB positively modulates the functions of EPCs in AMI patients, showing its possible pivotal role in therapeutic vasculogenesis.
EETs are endogenous lipid epoxides and act as lipid mediators of many important biological functions in the cardiovascular system [9, 56] . They are catalytically produced from arachidonic acid by epoxygenase or CYP enzymes [57] . Conversion of EETs to their corresponding diols (dihydroxyeicosatrienoic acids, DHETs) by sEH is responsible for decreasing EET levels and diminishing EETs' beneficial cardiovascular properties. Accordingly, we evaluated the effects of sEH inhibitor t-AUCB on EET concentrations. EETs were found to be dose dependently increased by t-AUCB, which indicated that the effect of t-AUCB on EPCs is through the effective inhibition of sEH.
EETs have been shown to increase VEGF and have angiogenic properties [58] , and they are endogenous activators and ligands of PPARγ [26] . Therefore, we hypothesized that the EETs-PPARγ pathway is responsible for the mechanism underlying the effect of t-AUCB on EPCs. First, we found that VEGF and HIF-1α expression was dose dependently increased by t-AUCB. However, GW9662, an antagonist of PPARγ ligands, abolished t-AUCB induced expression of VEGF and HIF-1α. Moreover, GW9662 markedly attenuated the concentration of EETs induced by t-AUCB. Thus, these results indicate that the angiogenic effects of the sEH inhibitor are facilitated by activating the EETs-PPARγ pathway, which in turn increases VEGF and HIF-1α and triggers EPC migration and proliferation, eventually leading to angiogenesis. Therefore, the study not only shows the mechanism of sEHi angiogenesis, but also suggests that endogenous angiogenic EETs act in a PPARγ dependent fashion.
This study test the effects of sEH inhibition in EPCs isolated from AMI patients. The in vitro nature of the study presents several limitations. Whether the sEH inhibitor will be able to increase EETs to an effective dose to increase EPC angiogenic properties and whether that will translate in improved outcomes in AMI patients remains unknown. Additionally, it must be noted that the enrolled number of patients in the study was relatively small and the patients had high cardiovascular risk factors, which might cause bias.
Future work is needed to address these limitations and translate sEH inhibitor treatment to AMI patients. First, it must be demonstrated that sEHi has positive effects on EPCs in vivo. Currently, we are investigating this in a mouse model of AMI. Second, the effect of sEH inhibitor treated EPCs on the revascularization of coronary vessel in AMI patients needs to be observed. Third, the effect of sEH inhibitor on the numbers and activities of EPCs should be confirmed following sEH inhibitor treatment by AMI patients. Lastly, the usage of sEH inhibitor on preventing AMI occurrence or reoccurrence should be explored. 
Table 2
EETs concentration in the EPCs from AMI patients (mean ± SEM) (n = 10). 
Conclusions
In conclusion, sEH inhibitors have great potential to treat cardiovascular diseases, as advocated in Nature Reviews Drug Discovery by Dr. Imig [19] and the translation of sEH inhibitor treatment to the clinical setting has begun with phase II trials to target hypertension and type 2-diabetes [59] . The findings of this study open up new avenues of exploration for the use of sEH inhibitors as a novel therapy to stimulate EPC dependent revascularization in AMI patients. Lastly, we provide evidence of the underlying mechanism of these effects and insight into the mechanism of an endogenous angiogenesis pathway. 
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